Science Research Studies- Top Three Growth Hormone-Releasing Peptides (GHRPs)

Top Three Growth Hormone-Releasing Peptides (GHRPs)

Brief Summary

Growth hormone-releasing peptides, commonly abbreviated as GHRPs, are synthetic growth hormone secretagogues investigated for their interaction with the ghrelin receptor and growth hormone signalling. GHRPs are often confused with GHRH analogues, although the two groups activate different receptors. GHRPs primarily target the growth hormone secretagogue receptor, GHS-R1a, while GHRH compounds act through the GHRH receptor. In today’s research overview, we study three leading growth hormone-releasing peptides: GHRP-6, Hexarelin and Ipamorelin. We examine how each peptide works, the laboratory results reported in controlled models and the characteristics that distinguish these three important research compounds from one another.

No. 1 GHRP-6 – Growth Hormone-Releasing Peptide-6

GHRP-6 ranks first in this overview because it is one of the most established and widely studied growth hormone-releasing peptides. It is a synthetic hexapeptide consisting of six amino-acid residues, with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂. GHRP-6 functions primarily as an agonist of the growth hormone secretagogue receptor type 1a, commonly called GHS-R1a or the ghrelin receptor. Activation of this G-protein-coupled receptor initiates intracellular signalling associated with calcium mobilisation and growth hormone release from pituitary somatotroph cells. This pathway is separate from the GHRH receptor pathway, explaining why GHRP-6 and GHRH analogues are not interchangeable despite influencing related research endpoints. Laboratory studies using isolated pituitary cells have reported a rapid but relatively short-duration growth hormone response following exposure to GHRP-6. Further controlled animal research found that GHRP-6 produced measurable, dose-dependent changes in circulating growth hormone concentrations. Researchers have also examined the interaction between GHRP-6 and naturally occurring GHRH signalling, with experimental findings indicating that the two pathways may produce a greater combined response than either pathway studied independently. Because GHS-R1a is also involved in ghrelin-mediated appetite and energy-balance signalling, GHRP-6 research frequently includes food-intake behaviour, gastrointestinal activity and metabolic regulation as secondary endpoints. Some models have additionally recorded changes in ACTH and cortisol signalling, demonstrating that GHRP-6 may have a broader endocrine research profile than more selective GHRPs. These findings make GHRP-6 useful for studying receptor activation, growth hormone pulse generation, secretagogue interactions and ghrelin-linked signalling. Its extensive research history and clearly characterised mechanism support its position as number one among the top three GHRPs featured in this article. The reported findings remain model-specific and should not be interpreted beyond their individual experimental conditions.

No.2 Hexarelin – Potent GHRP and Ghrelin-Receptor Agonist

Hexarelin ranks second among these top growth hormone-releasing peptides because of its strong secretagogue activity and broader receptor research profile. Hexarelin is a synthetic hexapeptide derived from earlier GHRP structures and is commonly represented by the sequence His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂. Like GHRP-6, Hexarelin activates GHS-R1a rather than the GHRH receptor. Receptor activation stimulates intracellular signalling in pituitary somatotroph models, promoting the controlled release of stored growth hormone. Comparative animal experiments have reported a rapid and pronounced response after Hexarelin administration, with some study designs recording larger peak changes than those produced by GHRP-6 under matching conditions. Its potency has therefore made the Hexarelin peptide an important laboratory reference for examining growth hormone secretagogue pharmacology, receptor sensitivity and changes in signalling following repeated exposure. Research has found that sustained or repeated receptor stimulation may reduce subsequent responsiveness, a process commonly described as desensitisation. This feature gives researchers a way to investigate how GHS-R1a signalling adapts under different exposure schedules. Hexarelin research extends beyond the pituitary pathway because experimental evidence suggests that the compound may interact with additional binding sites, including CD36-associated pathways in cardiac tissue models. Preclinical investigations have consequently examined oxidative stress, cellular survival signalling, myocardial injury and tissue responses alongside conventional growth hormone endpoints. Some reported cardiovascular observations persisted in models with limited pituitary growth hormone production, suggesting that certain findings may involve direct peripheral mechanisms rather than the GH/IGF-1 axis alone. These broader findings distinguish Hexarelin from peptides studied almost exclusively for selective growth hormone release. However, results from different models cannot automatically be combined, and receptor expression, species, concentration and study duration can materially affect the outcome. Hexarelin’s potent GHS-R1a activity, extensive experimental history and potential secondary pathways support its position as number two in this ranked GHRP research overview. 

No. 3 Ipamorelin – Selective Growth Hormone Secretagogue

Ipamorelin ranks third in this overview and is especially notable for its comparatively selective growth hormone secretagogue profile. It is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂. Although Ipamorelin is sometimes incorrectly described as a GHRH peptide, pharmacological investigations demonstrate that it acts through a GHRP-like receptor pathway associated with GHS-R1a. It does not work as a conventional GHRH analogue. Foundational laboratory research examined Ipamorelin in isolated rat pituitary cells and controlled rat and swine models. The results showed potent, dose-dependent growth hormone release, with activity comparable to GHRP-6 in several experimental settings. In primary pituitary-cell research, Ipamorelin produced an EC₅₀ of approximately 1.3 nmol/L, compared with approximately 2.2 nmol/L for GHRP-6 under the reported conditions. Animal models also recorded substantial growth hormone responses, although the exact magnitude varied according to species, experimental design and measurement period. The defining feature of Ipamorelin peptide research is its selectivity. Whereas GHRP-6 and some related secretagogues produced measurable changes in ACTH and cortisol concentrations, Ipamorelin did not significantly increase those endpoints in the cited model, even at exposure levels far above the concentration required for growth hormone release. This narrower signalling profile made Ipamorelin valuable for research attempting to isolate growth hormone-related activity from broader endocrine effects. Additional preclinical studies have explored bone mineral measurements, body-composition endpoints, nitrogen balance and gastrointestinal motility. These results must be considered individually because activity observed in one model does not establish the same outcome in another. Ipamorelin’s receptor selectivity also does not mean that it lacks all secondary biological activity; GHS-R1a is distributed across several tissues and participates in multiple signalling networks. Nevertheless, its ability to stimulate growth hormone release with comparatively limited ACTH and cortisol responses distinguishes it from earlier growth hormone-releasing peptides and supports its number-three position in this article. 

Conclusion

GHRP-6, Hexarelin and Ipamorelin are three important growth hormone-releasing peptides used to investigate growth hormone secretion, ghrelin-receptor signalling and related endocrine pathways. Although all three are associated with GHS-R1a activation, their structures, potency, selectivity and secondary research findings are not identical.

GHRP-6 takes the number-one position because of its extensive research history, clearly characterised ghrelin-receptor activity and value in studies of growth hormone release, appetite signalling and GHRP–GHRH pathway interaction. Hexarelin ranks second because it produces strong secretagogue responses and has also generated research interest involving CD36-associated and peripheral tissue pathways. Ipamorelin ranks third while offering the most selective profile of the three, particularly in experiments comparing growth hormone release with ACTH and cortisol measurements.

The distinction between GHRPs and GHRH analogues remains essential. GHRP-6, Hexarelin and Ipamorelin primarily activate the growth hormone secretagogue or ghrelin receptor. By comparison, compounds such as Sermorelin, CJC-1295 and Tesamorelin are associated with the GHRH receptor. Both categories may influence connected growth hormone pathways, but they begin through different receptor mechanisms.